GrapheneDx technology
GrapheneDx’s home testing device uses a patented sensor design, graphene, and antibodies for accurate, real-time biomarker detection.
graphenedx.comCrawled Nov 11, 2026
GrapheneDx’s home testing device uses a patented sensor design, graphene, and antibodies for accurate, real-time biomarker detection.
GrapheneDx relocated its office and lab to Drydock Ave in Boston’s Seaport district in September 2021 to support its growth and technology development.
GrapheneDx, General Graphene Corporation, and Sapphiros partnered in 2023 to develop graphene-based biosensors for point-of-care and consumer medical diagnostics.
Sapphiros appointed Mike Musgnug as EVP of Strategy and CEO of GrapheneDX in September 2023.
News Filter by categoryCompany News Load More +
careers
The company aims to make advanced diagnostic technologies accessible to individuals for home testing.
GrapheneDx offers diagnostic technology for consumer and medical use.
GrapheneDx develops at-home diagnostic technology using graphene-based sensors for convenient health management.
GrapheneDx, General Graphene Corp, and Sapphiros form a strategic partnership to scale production of graphene-based biosensors for point-of-care and consumer diagnostics. The collaboration aims to enhance disease detection capabilities in medical devices. GrapheneDx specializes in in vitro diagnostics, targeting improved accuracy and accessibility in healthcare settings.
Mike Musgnug has joined **Sapphiros** as Executive Vice President of Strategy and CEO of **GrapheneDx**, a subsidiary of Sapphiros Group. He will oversee strategy and business development for Sapphiros while leading GrapheneDx’s operations. Musgnug previously held leadership roles before this appointment.
GrapheneDx moves its office and lab to Drydock Ave in Boston’s Seaport district starting September 1, 2021. The relocation supports the company’s growth and development of its advanced diagnostic technology. The expansion follows recent rapid scaling efforts.
KKR and former Smith & Nephew and Alere CEO Namal Nawana launch **Sapphiros**, a platform focused on developing next-generation diagnostic technologies. Sapphiros will invest in and support companies in this space, including a direct equity stake in **GrapheneDx**, a firm specializing in graphene-based diagnostic solutions. The initiative aims to accelerate innovation in medical diagnostics through strategic investments and operational expertise.

GrapheneDx makes graphene field-effect transistor biosensors for in vitro diagnostics.